Axxam SpA expands to U.S., opens office in Cambridge, Mass.
Grünenthal capitalizes on Axxam’s drug discovery platform and expertise to identify small molecule lead structures for its early pipeline in pain and inflammation Aachen, Germany and Milano, Italy, March 3, 2016: Grünenthal and Axxam announced today that they have entered into an integrated collaboration. The objective is to discover novel small molecule lead structures for the development of pain and inflammation therapeutics by combining Axxam’s drug discovery platform with Grünenthal’s expertise on emerging and innovative biological pathways and targets.